FindTrial
Sign In

â??Comparing topical Clindamycin - Adapalene with oral doxycycline 100mg versus topical Benzoyl peroxide - Adapalene with oral doxycycline 100mg in moderate to severe facial acne vulgaris

Comparative study of efficacy, safety and cost effectiveness of topical Clindamycin 1% - Adapalene 0.1% combination therapy with oral doxycycline versus topical Benzoyl peroxide 2.5% - Adapalene 0.1% combination therapy with oral doxycycline in case of moderate to severe facial acne vulgaris: A prospective, randomised, open label parallel studyâ??.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/02/050053
Enrollment
60
Registered
2023-02-24
Start date
Unknown
Completion date
Unknown
Last updated
2023-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L088- Other specified local infections of the skin and subcutaneous tissue

Interventions

Intervention1: prospective,randomized ,open label parallel study: Clindamycin 1% - Adapalene 0.1% combination therapy with oral doxycycline versus topical Benzoyl peroxide 2.5% - Adapalene 0.1% combin

Sponsors

tamil selvi
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Subjects of either gender. 2. Subjects of 12 to 30 years of age with moderate to severe facial acne vulgaris having >= 19 and

Exclusion criteria

Exclusion criteria: Patients already on anti-acne medication(topical or oral) in last one month. 2. Patients having nodulocystic lesions, acne conglobata, acne fulminans, secondary acne. 3. Patients unwilling to give written informed consent. 4. Patients with known hypersensitivity to benzoyl peroxide, clindamycin or adapalene and doxycycline. 5. Pregnant or lactating women.

Design outcomes

Primary

MeasureTime frame
Efficacy and safety assessed from baseline at 4 and 8 weeks cost effectiveness assessed at 8 weeksTimepoint: From baseline at the end of 4 and 8 weeks,—

Secondary

MeasureTime frame
Adverse event cost effectiveness evaluatedTimepoint: 2,4 AND 8 WEEKS—

Countries

India

Contacts

Public ContactTamil selvi

AIIMS,NAGPUR

gndakhale@aiimsnagpur.edu.in9850539353

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026